I kliniske forsøg var dopaminerge bivirkninger f. eks. dyskinesier hyppigere hos de patienter, der behandledes med entakapon og dopaminerge agonister (som f. eks. bromocriptin), selegilin eller amantadin sammenlignet med de patienter, der fik placebo sammen med agonisterne.
In clinical studies, undesirable dopaminergic effects, e. g. dyskinesia, were more common in patients who received entacapone and dopamine agonists (such as bromocriptine), selegiline or amantadine compared to those who received placebo with this combination.